U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C2H5NO2.Fe.O4S
Molecular Weight 226.974
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FERROGLYCINE SULFATE

SMILES

[Fe++].NCC(O)=O.[O-]S([O-])(=O)=O

InChI

InChIKey=ZITFTYGHYGPDAV-UHFFFAOYSA-L
InChI=1S/C2H5NO2.Fe.H2O4S/c3-1-2(4)5;;1-5(2,3)4/h1,3H2,(H,4,5);;(H2,1,2,3,4)/q;+2;/p-2

HIDE SMILES / InChI

Molecular Formula Fe
Molecular Weight 55.845
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C2H4NO2
Molecular Weight 74.0587
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula HO4S
Molecular Weight 97.071
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/3541174 | https://books.google.ru/books?id=7mxyBgAAQBAJ&pg=PA13&lpg=PA13&dq=%22ferrous+iodide%22+anemia&source=bl&ots=ZGyFhUiJZ4&sig=IZOhRVaGmlwX7GcqgoE6rnCsCa4&hl=ru&sa=X&ved=0ahUKEwjYu7PCyYHUAhWiQpoKHR6cCfcQ6AEIUjAJ#v=onepage&q=%22ferrous%20iodide%22&f=false

There is no information about biological and pharmacological application of Iron(II) fluoride (also known as ferrous fluoride). It is known, that this substance is used to catalyze some organic reactions.

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Unknown

Approved Use

Unknown
Palliative
Unknown

Approved Use

Unknown
Primary
Ferro Sanol Duodenal

Approved Use

Ferro Sanol is an iron substitute in case of latent or manifest iron deficiency with and without development of anaemia.
Curative
RADIOGARDASE

Approved Use

Insoluble Prussian blue is indicated for treatment of patients with known or suspected internal contamination with radioactive cesium and/or radioactive or non-radioactive thallium to increase their rates of elimination.

Launch Date

2003
PubMed

PubMed

TitleDatePubMed
Reactivity enhancement of iron sulfide nanoparticles stabilized by sodium alginate: Taking Cr (VI) removal as an example.
2017-07-05
Continuous sulfidogenic wastewater treatment with iron sulfide sludge oxidation and recycle.
2017-05-01
Atomic Layer Deposition of Iron Sulfide and Its Application as a Catalyst in the Hydrogenation of Azobenzenes.
2017-03-13
Synthesis of phosphabenzenes by an iron-catalyzed [2+2+2] cycloaddition reaction of diynes with phosphaalkynes.
2015-06-22
A practical and successful desensitization protocol for immediate hypersensitivity reactions to iron salts.
2014
Effect of abomasal ferrous lactate infusion on phosphorus absorption in lactating dairy cows.
2013-07
Tolerability of different oral iron supplements: a systematic review.
2013-04
Endothelial dysfunction and inflammation induced by iron oxide nanoparticle exposure: Risk factors for early atherosclerosis.
2011-06-10
The effect of iron treatment on adhesion molecules in patients with iron deficiency anemia.
2010-12
Bioleaching of heavy metals from sewage sludge by indigenous iron-oxidizing microorganisms using ammonium ferrous sulfate and ferrous sulfate as energy sources: a comparative study.
2009-11-15
Reversal of multidrug resistance by magnetic Fe3O4 nanoparticle copolymerizating daunorubicin and 5-bromotetrandrine in xenograft nude-mice.
2009
Decreased treatment failure rates following duodenal release ferrous glycine sulfate in iron deficiency anemia associated with autoimmune gastritis and Helicobacter pylori gastritis.
2007
Determination of water in ferrous lactate by near infrared reflectance spectroscopy with a fibre-optic probe.
1997-10
[Historical notes on the therapy of depression].
1986-11-22
[FERROUS ASPARTATE IN THERAPY].
1964-01-01
Clinical appraisal of drugs with special reference to a new chelate hematinic.
1957-07-11
[Ferrous lactate as an oral iron preparation for therapeutic use].
1954-11-27
THE USE OF FERROUS GLUCONATE IN THE TREATMENT OF HYPOCHROMIC ANEMIA.
1937-07
FERROUS IODIDE AND LINOLEIC ACID IN VITAMIN A DEFICIENCY. A REPLY TO CERTAIN CRITICISMS.
1932-11-11
THE ADMINISTRATION OF FERROUS IODIDE AND LINOLEIC ACID TO RATS DEPRIVED OF VITAMIN A.
1932-09-30
FERROUS IODIDE AS A SUBSTITUTE FOR VITAMIN A IN RATS.
1932-07-01
Patents

Sample Use Guides

Adults should usually take one capsule a day. In cases of pronounced iron deficiency, adults can be given a dosage 2 to 3 times higher at the beginning of therapy. A daily dose of more than 5 mg Fe2+/kg body weight should in-well founded exceptional cases not be exceeded.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:07:14 GMT 2025
Edited
by admin
on Mon Mar 31 18:07:14 GMT 2025
Record UNII
JGK960078D
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
FERROGLYCINE SULFATE
MI  
Common Name English
FERROGLYCINE SULFATE COMPLEX
WHO-DD  
Preferred Name English
(T-4)-(GLYCINATO-.KAPPA.N,.KAPPA.O) (SULFATO(2-)-.KAPPA.O,.KAPPA.O')FERRATE(1-) HYDROGEN (1:1)
Common Name English
FERROCONTIN
Brand Name English
FERROGLYCINE SULPHATE
Common Name English
Ferroglycine sulfate complex [WHO-DD]
Common Name English
FERROGLYCINE SULFATE [MI]
Common Name English
FERRATE(1-), (GLYCINATO-.KAPPA.N,.KAPPA.O)(SULFATO(2-)-.KAPPA.O,.KAPPA.O')-, HYDROGEN (1:1), (T-4)-
Systematic Name English
FERROSANOL
Brand Name English
FERROUS AMINOACETOSULFATE
Common Name English
IRON SULFATE-GLYCINE COMPLEX
Common Name English
PLESMET
Brand Name English
Code System Code Type Description
PUBCHEM
28366
Created by admin on Mon Mar 31 18:07:14 GMT 2025 , Edited by admin on Mon Mar 31 18:07:14 GMT 2025
PRIMARY
MERCK INDEX
m5336
Created by admin on Mon Mar 31 18:07:14 GMT 2025 , Edited by admin on Mon Mar 31 18:07:14 GMT 2025
PRIMARY Merck Index
SMS_ID
100000089994
Created by admin on Mon Mar 31 18:07:14 GMT 2025 , Edited by admin on Mon Mar 31 18:07:14 GMT 2025
PRIMARY
EVMPD
SUB26615
Created by admin on Mon Mar 31 18:07:14 GMT 2025 , Edited by admin on Mon Mar 31 18:07:14 GMT 2025
PRIMARY
CAS
17169-60-7
Created by admin on Mon Mar 31 18:07:14 GMT 2025 , Edited by admin on Mon Mar 31 18:07:14 GMT 2025
PRIMARY
CAS
1334-41-4
Created by admin on Mon Mar 31 18:07:14 GMT 2025 , Edited by admin on Mon Mar 31 18:07:14 GMT 2025
SUPERSEDED
FDA UNII
JGK960078D
Created by admin on Mon Mar 31 18:07:14 GMT 2025 , Edited by admin on Mon Mar 31 18:07:14 GMT 2025
PRIMARY
EPA CompTox
DTXSID20928095
Created by admin on Mon Mar 31 18:07:14 GMT 2025 , Edited by admin on Mon Mar 31 18:07:14 GMT 2025
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY